No. While nothing really headline grabbing results were very strong. Lots of good stuff, first ERT pipeline deal expected in weeks, pick up in AD related clinical trials on the horizon and they clearly see lots of upside in healthcare. Large and building revenue backlog approaching US$ 100 million if you take years 6 to 10 on the Eisai deal in to account and they pick up a Phase III on the Lilly AD drug. Sitting of AUD 22.5 million of net cash. It would seem the new CFO has made significant improvements to the clarity of the financials in the preso.
CGS Price at posting:
90.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)